Sudarshan Pharma Industries Ltd Business Overview - SOIC x StockScans Report

as of Jul 2026

Sudarshan Pharma Industries is a Mumbai-based pharmaceutical and specialty chemical maker built on a simple idea: replace what India imports from China by making it at home, from the raw material all the way to the finished pill. Founded in 2008 by brothers Hemal and Sachin Mehta as a specialty chemical trading firm, it has since climbed the value chain into manufacturing active pharmaceutical ingredients, intermediates, and branded generics, listing on the BSE SME Platform in March 2023. The recurring approach is vertical integration - controlling the chemistry from basic building blocks through to the final dosage form - so the company can promise supply security, regulatory-ready documentation, and prices that are not at the mercy of a single overseas supplier.

Business segments

A single integrated pharmaceutical and specialty chemical engine, organised across five deeply connected activities - specialty chemical sourcing, API manufacturing, oncology intermediates, finished formulations, and international trading - all fed by a shared R&D backbone.

1. Specialty chemicals and intermediates: the raw-material foundation

The company sources, distributes, and increasingly makes the high-purity solvents and performance chemicals that pharmaceutical and industrial customers need, using a cost-plus model that protects margins from price swings.

2. API and intermediates manufacturing: the import-substitution engine

This is where the company makes the active pharmaceutical ingredients themselves - most notably Vitamins B1 and B6, which it claims to be the first in India to manufacture under the government's PLI scheme.

3. Oncology APIs and intermediates: the dedicated cancer-chemistry subsidiary

Through its wholly owned subsidiary Ratna Lifesciences, the company operates a specialised manufacturing facility focused exclusively on oncology derivatives - a high-value, low-volume niche with significant barriers to entry.

4. Finished formulations and branded generics: the patient-facing business

The company makes oral liquids and capsules at its Palghar plant and sells branded and unbranded generics through its own field force across five Indian states, reaching hospitals and retail pharmacies directly.

5. Exports and international trading: the global reach

The company sells its own manufactured APIs and formulations into non-regulated markets across Eurasia, Africa, and the Middle East, while also sourcing chemicals from East Asian vendors for Indian customers.

Research and development

A DSIR-approved formulation centre in Dehradun, two university partnerships, and a bioplastic patent form the innovation engine that feeds new molecules and dosage forms into every business line.

Group structure and partners

The listed parent company sits atop nine subsidiaries - spanning oncology manufacturing, chemical trading, healthcare disposables, and international trading entities in Singapore, Dubai, Poland, and the USA - with promoters holding a 57.39% stake.